2022-06-16 08:00 Regulatory Interim
Significant events during the fourth quarter Significant events after the end of the period Audiocast: When: 16 June 2022 at 15.00 CET Where: https://tv.streamfabriken.com/biovica-international-q4-2021-2022 Phone numbers: SE: +46856642692, DK: +4578723252...
2022-06-13 10:00 Regulatory
Biovica today announced that the company’s blood test DiviTum®TKa was highlighted in an oral presentation on June 6th at the ASCO Annual Meeting from the BioItaLEE trial. The study results suggest that TKa can predict patients’ response...
2022-05-09 13:15 Regulatory
Biovica, active in cancer diagnostics, today announces that the company's blood test DiviTum®TKa will be included in one oral presentation and two abstracts/posters, at the world's largest cancer congress, ASCO Annual Meeting, June 3-7...
2022-04-28 18:00 Regulatory
Biovica, active in cancer diagnostics, today announces that the company has submitted its updated 510(k)-application to the U.S. Food and Drug Administration (FDA) to receive marketing authorization for the blood-based biomarker assay DiviTum®TKa...
2022-04-28 08:00 Regulatory
Biovica, active in cancer diagnostics, will host a Capital Markets Day on Tuesday May 17, 2022, from 14.00 to 16.30. Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa...
2022-03-22 09:30 Regulatory
Biovica, active in cancer diagnostics, today announced that positive results on CDK 4/6 standard therapy from a clinical study at the University of Nebraska Medical Center and Washington University School of Medicine, US, is published in npj Breast Cancer...
2022-03-15 08:00 Regulatory Interim
Significant events during the third quarter Significant events after the end of the period Audiocast: When: 15 March 2022 at 3 PM CET Where: https://tv.streamfabriken.com/biovica-international-q3-2021-2022 Phone numbers: SE: +46850558356, DK: +4582333194...
2022-03-14 18:55 Regulatory
Biovica, active in cancer diagnostics, today announces that the company will establish its own US CLIA lab for the launch of DiviTum®TKa on the US market. Biovica aims to have its lab operational and CLIA certified during third quarter 2022. Biovica...
2022-02-18 14:20 Regulatory
The Nomination Committee prior to the 2022 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December...
2022-02-14 10:40 Regulatory
Biovica, active in cancer diagnostics, today announces that the positive DiviTum®TKa results from the European multicenter study PYTHIA have been published in the highly ranked peer-reviewed scientific journal European Journal of Cancer (EJC). The...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No